NCT06242392尚未招募不适用
The Correlation Between Homologous Recombination Deficiency Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 250
- 主要终点
- Efficacy of PARP inhibitors in the treatment of ovarian cancer
研究概览
简要总结
Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment. The efficacy was evaluated according to RECIST criteria, comparing the correlation between different HRD statuses and the efficacy of PARP inhibitors in ovarian cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with ovarian cancer (any histological type) and possessing complete pathological hematoxylin and eosin (HE) stained slides and paraffin-embedded tissue blocks.
- •Patients must be 18 years of age or older.
- •Patients should not have concurrent multiple primary cancers.
- •Patients must undergo an MRI or CT scan prior to starting treatment.
- •According to RECIST (Response Evaluation Criteria In Solid Tumors) criteria, patients must have at least one measurable lesion.
- •Participants must provide informed consent, voluntarily cooperate with clinical follow-up, and sign an informed consent form.
排除标准
- •Patients who do not have accessible tumor tissue required for Homologous Recombination Deficiency (HRD) testing.
- •Patients whose clinical records are incomplete, making it impossible to effectively compare treatment efficacy.
- •Patients who are lost to follow-up and for whom subsequent treatment outcomes cannot be tracked.
结局指标
主要结局
Efficacy of PARP inhibitors in the treatment of ovarian cancer
时间窗: 2026-5-1
Progression-Free Survival (PFS) is used to evaluate the efficacy of PARP inhibitor treatment in ovarian cancer with different HRD (Homologous Recombination Deficiency) statuses.
次要结局
- PARP inhibitors in the treatment of ovarian cancer(2026-5-1)
- cost-effectiveness analysis of using PARP inhibitors to treat cervical cancer(2026-5-1)
研究者
相似试验
终止
2 期
Functional Analysis of BRCAnessOvarian Neoplasm EpithelialHomologous Recombination DeficiencyBRCA1 MutationBRCA2 MutationNCT04780945Leiden University Medical Center27
招募中
不适用
Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.Ovarian CancerNCT05458973Yonsei University100
Unknown
不适用
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian CancerClinical MarkerPARP InhibitorOvarian CancerNCT04582552Xiaoxiang Chen60
招募中
2 期
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPiOvarian CancerNCT05551208Chongqing University Cancer Hospital42
招募中
不适用
Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR InhibitorsOvarian CancerNCT05640024Yonsei University54